Just weeks after Russia announced its SARS-CoV-2 vaccine, a preliminary study published in The Lancet reports encouraging findings: the vaccine triggers a robust immune response with no serious adverse effects.
On August 11, 2020, Russian President Vladimir Putin announced the registration of the world's first officially approved COVID-19 vaccine, Sputnik V, slated for mass rollout starting January 1, 2021. Despite initial skepticism from global health authorities—including a cautionary note from the WHO—several countries in Latin America, the Middle East, and Asia had already placed orders.
A study published in The Lancet on September 4, 2020, by Russian researchers validates these claims with data, offering encouraging preliminary results.
Sputnik V is a viral vector vaccine using two modified human adenoviruses as carriers for the SARS-CoV-2 spike protein. It involves two doses administered three weeks apart, each with a different adenovirus to enhance efficacy.
The study details two Phase I clinical trials involving 76 healthy volunteers from June 18 to August 3, 2020, testing different formulations. No serious adverse effects were reported from either component. Crucially, the two-dose regimen elicited strong antibody production against SARS-CoV-2.
However, as the researchers note, these results confirm immunogenicity but not protective efficacy against infection. Larger Phase II/III trials are essential for definitive proof.
Globally, 176 COVID-19 vaccines were in development as of then, with 34 in clinical trials—including 8 in Phase III, such as Moderna's candidate, which shared Phase I data in late July 2020.
